Lalage M Wakefield

List of Publications by Year
in descending order

106 papers	18,601 citations	31902 53 h-index	28224 105 g-index
108 all docs	108 docs citations	108 times ranked	15450 citing authors

#	Article	IF	Citations
1	Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies. Cancer Cell, 2022, 40, 231-232.	7.7	9
2	Aging and CNS Myeloid Cell Depletion Attenuate Breast Cancer Brain Metastasis. Clinical Cancer Research, 2021, 27, 4422-4434.	3.2	15
3	Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. Nature Methods, 2021, 18, 1181-1191.	9.0	82
4	Live tumor imaging shows macrophageÂinduction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination. Nature Communications, 2021, 12, 7300.	5.8	53
5	The Outcome of TGFÎ² Antagonism in Metastatic Breast Cancer Models <i>In Vivo</i> Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFÎ². Clinical Cancer Research, 2020, 26, 643-656.	3.2	16
6	Peptidylarginine Deiminase IV Regulates Breast Cancer Stem Cells via a Novel Tumor Cellâ€"Autonomous Suppressor Role. Cancer Research, 2020, 80, 2125-2137.	0.4	18
7	SOD2 acetylation on lysine 68 promotes stem cell reprogramming in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23534-23541.	3.3	57
8	Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein. Cell Death and Disease, 2019, 10, 689.	2.7	8
9	The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription. Nature Communications, 2019, 10, 2071.	5.8	60
10	Genetic insights into the morass of metastatic heterogeneity. Nature Reviews Cancer, 2018, 18, 211-223.	12.8	140
11	Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget, 2018, 9, 23462-23481.	0.8	9
12	Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. Journal of the National Cancer Institute, 2017, 109, djw189.	3.0	98
13	Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget, 2017, 8, 30621-30643.	0.8	80
14	Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to Matrin 3. ELife, 2017, 6, .	2.8	68
15	Quantitation of TGF-Î² proteins in mouse tissues shows reciprocal changes in TGF-Î²1 and TGF-Î²3 in normal vs neoplastic mammary epithelium. Oncotarget, 2016, 7, 38164-38179.	0.8	17
16	Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics. Journal of Translational Medicine, 2015, 13, 182.	1.8	38
17	A Flexible Reporter System for Direct Observation and Isolation of Cancer Stem Cells. Stem Cell Reports, 2015, 4, 155-169.	2.3	110
18	Growth differentiation factor-15 encodes a novel microRNA 3189 that functions as a potent regulator of cell death. Cell Death and Differentiation, 2015, 22, 1641-1653.	5.0	30

#	Article	IF	Citations
19	Immune-mediated pathology in Duchenne muscular dystrophy. Science Translational Medicine, 2015, 7, 299rv4.	5.8	209
20	A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. Oncogene, 2015, 34, 1094-1104.	2.6	66
21	Differential Proteome Analysis Identifies TGF-Î²-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model. PLoS ONE, 2015, 10, e0126483.	1.1	20
22	Effective Chemoimmunotherapy with Anti-TGFÎ² Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer. PLoS ONE, 2014, 9, e85398.	1.1	43
23	Synergistic antitumor effects of a TGFÎ² inhibitor and cyclophosphamide. OncoImmunology, 2014, 3, e28247.	2.1	7
24	Brightfield Proximity Ligation Assay Reveals Both Canonical and Mixed Transforming Growth Factor-Î²/Bone Morphogenetic Protein Smad Signaling Complexes in Tissue Sections. Journal of Histochemistry and Cytochemistry, 2014, 62, 846-863.	1.3	16
25	An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-Î² in human breast cancer. Breast Cancer Research, 2014, 16, R57.	2.2	19
26	Definition of Smad3 Phosphorylation Events That Affect Malignant and Metastatic Behaviors in Breast Cancer Cells. Cancer Research, 2014, 74, 6139-6149.	0.4	33
27	A p21-ZEB1 Complex Inhibits Epithelial-Mesenchymal Transition through the MicroRNA 183-96-182 Cluster. Molecular and Cellular Biology, 2014, 34, 533-550.	1.1	92
28	Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells. Oncotarget, 2014, 5, 7635-7650.	0.8	21
29	Beyond TGFÎ²: roles of other TGFÎ² superfamily members in cancer. Nature Reviews Cancer, 2013, 13, 328-341.	12.8	352
30	SDF-1Î± Mediates Wound-Promoted Tumor Growth in a Syngeneic Orthotopic Mouse Model of Breast Cancer. PLoS ONE, 2013, 8, e60919.	1.1	6
31	Expression of the B-Cell Receptor Component CD79a on Immature Myeloid Cells Contributes to Their Tumor Promoting Effects. PLoS ONE, 2013, 8, e76115.	1.1	57
32	Biological Responses to TGF-Î² in the Mammary Epithelium Show a Complex Dependency on Smad3 Gene Dosage with Important Implications for Tumor Progression. Molecular Cancer Research, 2012, 10, 1389-1399.	1.5	18
33	TGF-Î²-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. Journal of Lipid Research, 2012, 53, 2698-2707.	2.0	28
34	Expression of TGF-Î² signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Research and Treatment, 2010, 121, 727-735.	1.1	51
35	Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines. PLoS ONE, 2010, 5, e9201.	1.1	130
36	A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGFÎ² signaling in the mammary gland. Breast Cancer Research, 2010, 12, R83.	2.2	22

#	Article	IF	Citations
37	Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer. Cancer Letters, 2010, 287, 172-181.	3.2	29
38	Modeling metastasis biology and therapy in real time in the mouse lung. Journal of Clinical Investigation, 2010, 120, 2979-2988.	3.9	79
39	Transient Tumor-Fibroblast Interactions Increase Tumor Cell Malignancy by a TGF-Î² Mediated Mechanism in a Mouse Xenograft Model of Breast Cancer. PLoS ONE, 2010, 5, e9832.	1.1	78
40	Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-Î². Immune Network, 2009, 9, 122.	1.6	17
41	Progressive Tumor Formation in Mice with Conditional Deletion of TGF-Î² Signaling in Head and Neck Epithelia Is Associated with Activation of the PI3K/Akt Pathway. Cancer Research, 2009, 69, 5918-5926.	0.4	92
42	Identification of Novel Gene Amplifications in Breast Cancer and Coexistence of Gene Amplification with an Activating Mutation of <i>PIK3CA</i>. Cancer Research, 2009, 69, 7357-7365.	0.4	104
43	Transforming Growth Factor-Î²s and Mammary Gland Involution; Functional Roles and Implications for Cancer Progression. Journal of Mammary Gland Biology and Neoplasia, 2009, 14, 131-144.	1.0	65
44	TGF-Î² modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. Cancer Immunology, Immunotherapy, 2009, 58, 1809-1818.	2.0	26
45	An Antiâ€"Transforming Growth Factor Î² Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments. Cancer Research, 2008, 68, 3835-3843.	0.4	203
46	Acute Wounds Accelerate Tumorigenesis by a T Cellâ€"Dependent Mechanism. Cancer Research, 2008, 68, 7278-7282.	0.4	59
47	Transforming Growth Factor Î² Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17. Cancer Research, 2008, 68, 3915-3923.	0.4	233
48	Transforming Growth Factor-Î² Can Suppress Tumorigenesis through Effects on the Putative Cancer Stem or Early Progenitor Cell and Committed Progeny in a Breast Cancer Xenograft Model. Cancer Research, 2007, 67, 8643-8652.	0.4	97
49	Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models. Clinical Cancer Research, 2007, 13, 2168-2177.	3.2	44
50	Dysadherin: A new player in cancer progression. Cancer Letters, 2007, 255, 161-169.	3.2	64
51	Lentiviral reporter constructs for fluorescence tracking of the temporospatial pattern of Smad3 signaling. BioTechniques, 2007, 43, 289-294.	0.8	6
52	Keeping Order in the Neighborhood: New Roles for TGFÎ² in Maintaining Epithelial Homeostasis. Cancer Cell, 2007, 12, 293-295.	7.7	34
53	Development of Oncolytic Adenovirus Armed with a Fusion of Soluble Transforming Growth Factor-Î² Receptor II and Human Immunoglobulin Fc for Breast Cancer Therapy. Human Gene Therapy, 2006, 17, 1152-1161.	1.4	45
54	Chemokine (C-C Motif) Ligand 2 Mediates the Prometastatic Effect of Dysadherin in Human Breast Cancer Cells. Cancer Research, 2006, 66, 7176-7184.	0.4	94

#	Article	IF	Citations
55	Bone Sialoprotein Mediates the Tumor Cellâ€"Targeted Prometastatic Activity of Transforming Growth Factor Î² in a Mouse Model of Breast Cancer. Cancer Research, 2006, 66, 6327-6335.	0.4	93
56	Development of Oncolytic Adenovirus Armed with a Fusion of Soluble Transforming Growth Factor-?Receptor II and Human Immunoglobulin Fc for Breast Cancer Therapy. Human Gene Therapy, 2006, .	1.4	0
57	IL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-Î² Independent. Journal of Immunology, 2004, 173, 4020-4029.	0.4	337
58	The two faces of transforming growth factor Â in carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8621-8623.	3.3	732
59	TGF-Î² switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. Journal of Clinical Investigation, 2003, 112, 1116-1124.	3.9	204
60	TGF-Î² switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. Journal of Clinical Investigation, 2003, 112, 1116-1124.	3.9	318
61	Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Research, 2003, 63, 8284-92.	0.4	155
62	Disruption of Transforming Growth Factor Î² Signaling by a Novel Ligand-dependent Mechanism. Journal of Experimental Medicine, 2002, 195, 1247-1255.	4.2	37
63	Latent Transforming Growth Factor-Î² Activation in Mammary Gland. American Journal of Pathology, 2002, 160, 2081-2093.	1.9	138
64	Independent Regulation of Transforming Growth Factor-Î²1 Transcription and Translation by Glucose and Platelet-Derived Growth Factor. American Journal of Pathology, 2002, 161, 1039-1049.	1.9	63
65	TGF-ÃŽÂ² signaling: positive and negative effects on tumorigenesis. Current Opinion in Genetics and Development, 2002, 12, 22-29.	1.5	796
66	Validation of transgenic mammary cancer models: goals of the NCI Mouse Models of Human Cancer Consortium and the mammary cancer CD-ROM. Transgenic Research, 2002, 11, 635-636.	1.3	5
67	Lifetime exposure to a soluble TGF-Î² antagonist protects mice against metastasis without adverse side effects. Journal of Clinical Investigation, 2002, 109, 1607-1615.	3.9	189
68	Lifetime exposure to a soluble TGF-Î² antagonist protects mice against metastasis without adverse side effects. Journal of Clinical Investigation, 2002, 109, 1607-1615.	3.9	326
69	Smad3 in the mammary epithelium has a nonredundant role in the induction of apoptosis, but not in the regulation of proliferation or differentiation by transforming growth factor-beta. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 2002, 13, 123-30.	0.8	22
70	Heterozygous inactivation of TGF-Î²1 increases the susceptibility to chemically induced mouse lung tumorigenesis independently of mutational activation of K-ras. Toxicology Letters, 2001, 123, 151-158.	0.4	10
71	Translational Regulation of Renal Proximal Tubular Epithelial Cell Transforming Growth Factor-Î²1 Generation by Insulin. American Journal of Pathology, 2001, 159, 1905-1915.	1.9	68
72	TGF-beta signaling in mammary gland development and tumorigenesis. Journal of Mammary Gland Biology and Neoplasia, 2001, 6, 67-82.	1.0	84

#	Article	IF	Citations
73	Enhanced tumorigenesis and reduced transforming growth factor-? type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-?1. Molecular Carcinogenesis, 2000, 29, 112-126.	1.3	22
74	The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene, 2000, 19, 968-988.	2.6	455
75	Transforming growth factors-Î² are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system. Breast Cancer Research, 2000, 3, 66-75.	2.2	3
76	Transforming growth factor-Î² and breast cancer: Lessons learned from genetically altered mouse models. Breast Cancer Research, 2000, 2, 100-6.	2.2	40
77	TRANSFORMING GROWTH FACTOR-b1 AND ITS RECEPTORS IN HUMAN LUNG CANCER AND MOUSE LUNG CARCINOGENESIS. Experimental Lung Research, 2000, 26, 685-707.	0.5	23
78	Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Research and Treatment, 1999, 57, 277-283.	1.1	30
79	Transforming growth factor-Î²1 is a new form of tumor suppressor with true haploid insufficiency. Nature Medicine, 1998, 4, 802-807.	15.2	296
80	Identification of the start sites for the 1.9- and 1.4-kb rat transforming growth factor-Î²1 transcripts and their effect on translational efficiency. Gene, 1998, 219, 81-89.	1.0	17
81	Translational Control Elements in the Major Human Transforming Growth Factor-Î²1 mRNA. Growth Factors, 1998, 16, 89-100.	0.5	21
82	Recharacterization of the start sites for the major human transforming growth factor-Î²1 mRNA. Gene, 1997, 189, 289-295.	1.0	9
83	Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas. EMBO Journal, 1997, 16, 2621-2633.	3.5	222
84	Modulation of B16 Melanoma Growth and Metastasis by Anti-Transforming Growth Factor ?? Antibody and Interleukin-2. Journal of Immunotherapy, 1996, 19, 169-175.	1.2	57
85	The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 5877-5882.	3.3	145
86	Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. British Journal of Cancer, 1996, 74, 352-358.	2.9	32
87	Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2572-2576.	3.3	635
88	Inhibition of the chondrocyte phenotype by retinoic acid involves upregulation of metalloprotease genes independent of TGF-?. Journal of Cellular Physiology, 1994, 159, 340-346.	2.0	46
89	TGF-Î²1 Prevents Hypertrophy of Epiphyseal Chondrocytes: Regulation of Gene Expression for Cartilage Matrix Proteins and Metalloproteases. Developmental Biology, 1993, 158, 414-429.	0.9	225
90	Addition of a C-Terminal Extension Sequence to Transforming Growth Factor-pl Interferes with Biosynthetic Processing and Abolishes Biological Activity. Growth Factors, 1991, 5, 243-253.	0.5	11

#	Article	IF	Citations
91	Latent Forms of Transforming Growth Factor-Î² (TGFÎ²) Derived from Bone Cultures: Identification of a Naturally Occurring 100-kDa Complex with Similarity to Recombinant Latent TGFÎ². Molecular Endocrinology, 1991, 5, 741-751.	3.7	121
92	Physicochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1, 2, and 3. Growth Factors, 1990, 3, 35-43.	0.5	324
93	Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution.. Journal of Clinical Investigation, 1990, 86, 1976-1984.	3.9	279
94	Recombinant TGF-Î²1 is Synthesized as a Two-Component Latent Complex that Shares Some Structural Features with the Native Platelet Latent TGF-Î²1 Complex. Growth Factors, 1989, 1, 203-218.	0.5	115
95	Transforming Growth Factor-?: Multifunctional Regulator of Cell Growth and Phenotype. Annals of the New York Academy of Sciences, 1988, 551, 290-298.	1.8	32
96	Distribution and modulation of the cellular receptor for transforming growth factor-beta.. Journal of Cell Biology, 1987, 105, 965-975.	2.3	519
97	Evidence that transforming growth factor-Î² is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 1987, 48, 417-428.	13.5	954
98	Some recent advances in the chemistry and biology of transforming growth factor-beta.. Journal of Cell Biology, 1987, 105, 1039-1045.	2.3	1,277
99	Structure and properties of the cellular receptor for transforming growth factor type beta. Biochemistry, 1986, 25, 3083-3091.	1.2	101
100	Transforming growth factor-beta: biological function and chemical structure. Science, 1986, 233, 532-534.	6.0	1,192
101	Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 2438-2442.	3.3	528
102	Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 4167-4171.	3.3	2,691
103	Type beta transforming growth factor: a bifunctional regulator of cellular growth.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 119-123.	3.3	1,056
104	Isolation of a membrane protein by chromatofocusing: Cytochrome b-561 of the adrenal chromaffin granule. Journal of Proteomics, 1984, 9, 331-341.	2.4	31
105	The role of phospholipids in the modulation of enzyme activities in the chromaffin granule membrane. Biochimica Et Biophysica Acta - Biomembranes, 1981, 643, 363-375.	1.4	25
106	Reconstitution of the Mg2+ -ATPase of the chromaffin granule membrane. FEBS Letters, 1979, 103, 323-327.	1.3	23